The present invention describes methods of using Olfr90 demonstrated to bind to fungal metabolites, including a metabolite known to be detected in patients with mold (e.g. Aspergillus) infections.

The present invention describes methods of using Olfr90 demonstrated to bind to fungal metabolites, including a metabolite known to be detected in patients with mold (e.g. Aspergillus) infections.

A iontophoresis method (700) is described for delivering vitamin C through the skin of a biological subject, the method comprising applying (702) a selected current profile, either continuous direct current or pulsed current or a combination of both to a biological subject. A iontophoresis composition is further described, comprising one or more of vitamin C, vitamin C derivatives, ions of vitamin C and ions of vitamin C derivatives and further comprising a silicon material and water. A iontophoresis kit for carrying out the iontophoresis method is also disclosed. The application further describes a iontophoresis device comprising an electrode assembly and circuitry configured to concurrently generate a continuous direct current stimulus and a pulsed current stimulus; a corresponding iontophoresis method for delivering a cosmetic composition to a biological subject is also disclosed.

A iontophoresis method (700) is described for delivering vitamin C through the skin of a biological subject, the method comprising applying (702) a selected current profile, either continuous direct current or pulsed current or a combination of both to a biological subject. A iontophoresis composition is further described, comprising one or more of vitamin C, vitamin C derivatives, ions of vitamin C and ions of vitamin C derivatives and further comprising a silicon material and water. A iontophoresis kit for carrying out the iontophoresis method is also disclosed. The application further describes a iontophoresis device comprising an electrode assembly and circuitry configured to concurrently generate a continuous direct current stimulus and a pulsed current stimulus; a corresponding iontophoresis method for delivering a cosmetic composition to a biological subject is also disclosed.

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R.sup.1a, R.sup.2a, .sup.A1, A.sup.2, A.sup.3, A.sup.4, R.sup.1b, R.sup.2b, B.sup.1, B.sup.2, B.sup.3, and G are as set forth in the specification, as well as to methods for their preparation, N pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

##STR00001##

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R.sup.1a, R.sup.2a, .sup.A1, A.sup.2, A.sup.3, A.sup.4, R.sup.1b, R.sup.2b, B.sup.1, B.sup.2, B.sup.3, and G are as set forth in the specification, as well as to methods for their preparation, N pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

##STR00001##

The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.

The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.

The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.

Disclosed herein are gastrointestinal tract (G1) bacteria and methods for treating or preventing an irradiation-induced intestinal damage in a subject, the methods comprising administering a G1 bacterium to the subject, wherein the G1 bacterium comprises a vector that comprises a polynucleotide encoding IL-22 and/or IFN-P, or a functional fragment thereof.